MaaT Pharma (EPA:MAAT) CHMP rejection shifts attention to September appeal, cash runway
MaaT Pharma plans to ask for a re-examination of Xervyteg after European regulators rejected the drug. The French biotech’s lead asset will face another look in September, a move that could decide both the drug’s future and the company’s balance sheet.
Company hubEPA:MAAT
MAAT (MAAT) Stock News & Analysis
Follow the latest MAAT (MAAT) company news, earnings coverage and investor analysis from TechStock².
Save this hub to your TS2 Signalbook account.
- Latest update
- Articles in this hub
- 1
- Last 30 days
- 0
What investors are watching
- Earnings, guidance and financial performance
- Valuation, trading activity and market sentiment
- Strategy, catalysts and company-specific risks
TechStock² Updates
